Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics
HACKENSACK, NJ and Toronto, Canada – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, announced today a therapeutic development partnership. The partnership will combine […]
Cyclica and Arctoris to expand partnership to advance drug discovery programs for Alzheimer’s disease
Toronto, Canada and Oxford, UK — Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Arctoris Ltd. (“Arctoris”), a tech-enabled biopharma company that combines its unique automation with computational approaches to progress drug discovery, have agreed to expand their partnership to progress drug discovery programs […]
Cyclica CEO Naheed Kurji named Chair of the AAIH
Rapidly growing advocacy organization for the responsible adoption of AI/ML technology across life sciences and healthcare enters its fourth year Baltimore, Md. — Alliance for Artificial Intelligence in Healthcare (AAIH), a 501(c)(4) non-profit advocacy and educational organization dedicated to promoting the development and implementation of AI in healthcare, has appointed a new slate of Board […]
Cyclica announces 10 new academic partnerships to support small molecule drug discovery
Toronto, Canada — Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, is committed to supporting growth in academic research, the basis of numerous drug discoveries which impact patients’ lives. Recently, Cyclica has entered partnerships with the following academic institutions in the respective therapeutic areas below: […]
Cyclica launches Perturba Therapeutics, a spin out from the University of Toronto, creating the next-generation oncology biotech
Toronto, Canada — Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, today launches Perturba Therapeutics Inc. (“Perturba”), a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from […]
Cyclica recruits big pharma veteran Michael Palovich as Chief Science Officer to advance robust drug discovery pipeline
Toronto, Canada — Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, welcomes drug discovery veteran Michael (Mike) Palovich as Chief Science Officer, Head of Drug Discovery. Mike brings 24 years of drug discovery experience at GlaxoSmithKline (GSK), where he led drug discovery programs spanning multiple […]
Cyclica and ImmuneMed Form Agreement to Collectively Develop Pancreatic Cancer Therapeutics
Toronto, Canada and Seoul, Republic of Korea — Cyclica Inc. (“Cyclica”), the partner of choice for data driven drug discovery, and ImmuneMed Inc. (“ImmuneMed”), a developer of treatments for viral and inflammatory diseases, announce a collaboration to discover and develop small molecule therapeutics for pancreatic cancer. Pursuant to the collaboration, Cyclica will screen, identify and […]
Cyclica and the Structural Genomics Consortium co-crystallize DCAF1, a key component in proteasomal degradation, with a novel ligand to support targeted therapeutics discovery
Toronto, Canada — Cyclica, the partner of choice for data-driven drug discovery, and the Structural Genomics Consortium (SGC), a global public-private partnership dedicated to open science, have collaborated on a project in support of Target 2035, an initiative to discover probe molecules in support of developing medicines for all. As part of the initiative, the […]
Cyclica and IMPACT Therapeutics Team Up to Advance Differentiated Anti-cancer Drug Development
21 September, 2021, Toronto, Canada and Shanghai, China — Cyclica, the partner of choice for data-driven drug discovery, and IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics with synthetic lethality approach, announce today that they have entered to a collaboration agreement on IMPACT Therapeutics’ differentiated targeted anti-cancer drug […]
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cure Collaboration creates opportunities to identify, validate, and progress new medicines for CDD more rapidly and at a lower cost by derisking biological target and drug candidate selection CHERRY HILL, NJ and TORONTO, CANADA – August 19, 2021 – […]